Table 1.
Demographic and baseline characteristics of 103 HIV-infected patients who performed pharmacogenetic testing
| Variables | |
|---|---|
| Median (range) age at time of diagnosis (years) | 46 (20–85) |
| Sex, n (%) | |
| Male | 71 (68.9) |
| Female | 32 (31.1) |
| At pharmacogenetic testing | |
| Median (range) HIV RNA (copies/mL) | 8,261 (19–2,670,000) |
| Undetectable (<40 copies/mL), n (%) | 54 (52.4) |
| Detectable, n (%) | 29 (28.2) |
| No data, n (%) | 20 (19.4) |
| After pharmacogenetic testing | |
| Median (range) HIV RNA (copies/mL) | 39 (19–610,068) |
| Undetectable (<40 copies/mL), n (%) | 76 (73.8) |
| Detectable, n (%) | 17 (16.5) |
| No data, n (%) | 10 (9.7) |
| At pharmacogenetic testing | |
| Median (range) CD4 cell count (cells/mm3) | 329 (11–1,121) |
| ≤200 | 25 (24.3) |
| 201–350 | 31 (30.1) |
| 351–500 | 23 (22.3) |
| >500 | 19 (18.4) |
| No data | 5 (4.9) |
| After pharmacogenetic testing | |
| Median (range) CD4 cell count (cells/mm3) | 404 (19–1,073) |
| ≤200 | 13 (12.6) |
| 201–350 | 18 (17.4) |
| 351–500 | 33 (32.0) |
| >500 | 32 (31.1) |
| No data | 7 (6.80) |
| Treatment status at the end of the study | |
| Naive, n (%) | 2 (2.0) |
| On antiretroviral therapy, n (%) | 100 (97.1) |
| Tenofovir, lamivudine, efavirenz, n (%) | 26 (25.2) |
| Tenofovir, emtricitabine, efavirenz, n (%) | 22 (21.4) |
| Zidovudine, lamivudine, nevirapine, n (%) | 7 (6.8) |
| No data, n (%) | 1 (0.9) |
Abbreviation: HIV, human immunodeficiency virus.